Companies › Lee's Pharmaceutical
4 active drug programs in 20 registered trials: 7 Phase 3, 7 Phase 1, 5 Phase 4, 1 Phase 2; Oncology, Cardiovascular, Gastroenterology, Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Socazolimab IL-17A inhibitor | – | Phase 3 | Cervical Cancer | Sep 2027 |
| 5-Aminolevulinic Acid Hydrochloride Powder for Oral Solution 5-ALA is a prodrug that accumulates protoporphyrin IX in tumor cells; fluorescence is used | PPOX | Phase 3 | 5-aminolevulinic Acid | Dec 2027 |
| AU409 | – | Phase 1 | Advanced Hepatocellular Carcinoma | – |
| Fentanyl Mu opioid receptor agonist | OPRM1 | Phase 1 | Cancer; Vaginal Delivery; Spinal Anesthesia Duration; Effect of Drug … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06823349 | Fentanyl | Phase 4 | Vaginal Delivery | Other | Jun 2025 |
| NCT07078201 | Fentanyl | Phase 4 | Spinal Anesthesia Duration | Other | Jul 2025 |
| NCT06479655 | Fentanyl | Phase 4 | Effect of Drug | Other | Nov 2025 |
| NCT06917898 | Fentanyl | Phase 1 | Healthy Female Volunteer | Other | Apr 2026 |
| NCT06953453 | Fentanyl | Phase 1 | Cancer | Oncology | Jul 2026 |
| NCT06374485 | AU409 | Phase 1 | Advanced Hepatocellular Carcinoma | Oncology | Aug 2026 |
| NCT07911943 | Fentanyl | Phase 1 | Intra and Post Operative Pain Management | Other | Nov 2026 |
| NCT07165262 | Fentanyl | Phase 3 | Epilepsy | Oncology | Mar 2027 |
| NCT07443254 | Fentanyl | Phase 1 | Anesthesia | Other | Apr 2027 |
| NCT06281951 | Fentanyl | Phase 1 | Analgesia | Other | Jun 2027 |
| NCT06281951 | Fentanyl | Phase 1 | Analgesia | Other | Jun 2027 |
| NCT07120763 | Fentanyl | Phase 3 | Distal Radius Fracture Reduction | Other | Aug 2027 |
| NCT04011150 | Fentanyl | Phase 3 | Labor Pain | Other | Aug 2027 |
| NCT06459687 | Socazolimab | Phase 3 | Cervical Cancer | Oncology | Sep 2027 |
| NCT07840183 | Fentanyl | Phase 4 | Ventral Hernia | Gastroenterology | Sep 2027 |
| NCT06160492 | 5-Aminolevulinic Acid Hydrochloride Powder for Oral Solution | Phase 3 | 5-aminolevulinic Acid | Oncology | Dec 2027 |
| NCT02278601 | Fentanyl | Phase 3 | Breakthrough Pain | Other | Dec 2027 |
| NCT03167905 | Fentanyl | Phase 2 | Depression, Postpartum | Psychiatry | Dec 2027 |
| NCT06464146 | Fentanyl | Phase 3 | Limb Injury | Other | Feb 2028 |
| NCT07556523 | Fentanyl | Phase 4 | Transcatheter Aortic Valve Replacement (TAVR) | Cardiovascular | Apr 2028 |
InxMed (Shanghai) Clarity Pharmaceuticals TYK Medicines Impact Therapeutics TransThera Sciences (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.